Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 27INDUSTRY 26NIH 6NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1

Conditions

Neuroblastoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Hepatoblastoma 1

Interventions

Radiotherapy 299Cisplatin 263Cyclophosphamide 229Doxorubicin 176Paclitaxel 166Vincristine 160Carboplatin 149Filgrastim 139Etoposide 139Gemcitabine 118Fluorouracil 113Docetaxel 112Methotrexate 106Dexamethasone 106Cytarabine 106Prednisone 91Leucovorin 90Granulocyte Colony-Stimulating Factor 74Specimen Handling 65Magnetic Resonance Spectroscopy 61Capecitabine 59Irinotecan 58Radiation 54Ifosfamide 51Oxaliplatin 48Daunorubicin 48Temozolomide 47Radiotherapy, Conformal 47Platinum 47Peripheral Blood Stem Cell Transplantation 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Interventional × MLN 8237 × Clear all
NCT01154816 2020-05-13

Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia

Children's Oncology Group

Phase 2 Completed
118 enrolled 24 charts
CNSGastrointestinalLymphoidOther hematologic neoplasmSarcoma

Neuroblastoma, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02444884 2016-02-09

MLN8237 to Treat Children With Relapsed/Refractory Solid Tumors

Children's Oncology Group

Phase 1 Completed
54 enrolled
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡